Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional) | PAS 25 073

Opportunity Information: Apply for PAS 25 073

Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional) is an NIH funding opportunity (PAS-25-073) designed to expand and strengthen HIV/AIDS research that fits squarely within the scientific mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The main idea is to encourage investigators to pursue HIV-related questions where NIDDK has clear relevance, such as how HIV infection, HIV-associated inflammation, or antiretroviral therapy intersect with diabetes and other endocrine disorders, digestive and liver diseases, obesity and nutrition, and kidney and urologic conditions. Applications are expected to align with the NIH Office of AIDS Research (OAR) HIV/AIDS research priorities and the NIH guidelines used to determine whether work qualifies as HIV/AIDS research, as outlined in NOT-OD-20-018 (Update: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding). In practice, that means proposals should not only involve HIV, but should also map to recognized NIH HIV/AIDS priority areas while clearly advancing NIDDK-relevant science.

This opportunity uses the R01 mechanism, which is NIH's standard, investigator-initiated research project grant intended for substantial, multi-year research programs. The "Clinical Trial Optional" designation means you can propose either a study that does not involve a clinical trial or one that does, as long as it meets NIH definitions and is appropriate for the aims. That flexibility is helpful for projects that range from mechanistic studies in humans to intervention or implementation studies, provided the work is justified, feasible, and properly designed. The funding instrument is a grant, and the activity category is listed under Food and Nutrition and Health (CFDA 93.847), signaling the broader public health and biomedical scope while still being anchored in NIDDK's mission areas.

Eligibility is broad and includes many types of U.S. organizations and governmental entities. Standard NIH-eligible applicants listed here include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; Native American tribal organizations that are not federally recognized tribal governments; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses); and small businesses. The notice also explicitly highlights additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), as well as faith-based or community-based organizations. It further includes eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations), which is notable for applicants with international research components or collaborations where the science and public health justification is strong.

Administratively, the sponsoring agency is the National Institutes of Health, with NIDDK as the institute focus for mission alignment. The opportunity is categorized as discretionary funding, and the posted original closing date runs through January 7, 2028, indicating an extended window typical of NIH parent-like or priority-topic R01 announcements with multiple receipt dates over several years. The listing does not specify an award ceiling or expected number of awards in the provided source data, which usually means applicants should rely on standard NIH R01 budgeting norms, institute-specific budget guidance, and the scope of work to propose an appropriate budget. Overall, the NOFO is best understood as an open invitation for well-justified, hypothesis-driven HIV/AIDS research proposals that also meaningfully advance knowledge in diabetes, digestive disease, nutrition/obesity, or kidney/urologic health, while staying consistent with NIH-wide HIV/AIDS research priority frameworks set by OAR.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2025-01-08.
• Applicants must submit their applications by 2028-01-07.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAS 25 073

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: